Upgrade to SI Premium - Free Trial

Sarepta Therapeutics (SRPT) PT Raised To $230 At Nomura On Increasing Pipeline Success

February 28, 2019 6:23 AM
Nomura/Instinet analyst, Christopher Marai, reiterated his Buy rating on shares of Sarepta Therapeutics (NASDAQ: SRPT) and raised his price target ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst EPS Change Analyst EPS View Analyst PT Change

Next Articles